Table IV.
Results of univariate analysis of overall survival.
| Variable | Median survival time (months) | P-value |
|---|---|---|
| Histology: PSC vs. PA | 7.0 vs. 35.6 | 0.0256 |
| ECOG PS: 0–1 vs. 2–4 | 26.6 vs. 6.1 | 0.0063 |
| Sex: male vs. female | 13.1 vs. 13.6 | 0.4637 |
| Age: <75 vs. ≥75 | 13.1 vs. 21.5 | 0.6989 |
| Smoking status: never vs. past/current | 10.0 vs. 20.0 | 0.1319 |
| Clinical stage: IA-IIIA vs. IIIB-IV | 59.8 vs. 10.0 | 0.0080 |
| E-cadherin: low vs. high | 12.6 vs. 30.4 | 0.2166 |
| Vimentin: low vs. high | 38.7 vs. 7.3 | 0.0348 |
| Snail-1/Snail-2: low vs. high | 6.6 vs. 13.3 | 0.7065 |
| p-p38 MAPK: low vs. high | 13.0 vs. 13.3 | 0.7400 |
| NANOG: low vs. high | 12.6 vs. 26.6 | 0.4416 |
PSC, pulmonary sarcomatoid carcinoma; PA, pulmonary adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; p-p38 MAPK, phosphorylated p38 mitogen activated protein kinase; Snail, zinc finger protein SNAI; NANOG, homeobox protein NANOG.